AdvisorShares Psychedelics ETF (PSIL)
NYSEARCA: PSIL · IEX Real-Time Price · USD
0.940
-0.029 (-2.94%)
Jul 2, 2024, 3:59 PM EDT - Market closed
-2.94% (1D)
| Assets | $5.61M |
| Expense Ratio | 0.99% |
| PE Ratio | n/a |
| Shares Out | 5.80M |
| Dividend (ttm) | $0.00 |
| Dividend Yield | 0.36% |
| Ex-Dividend Date | Sep 25, 2023 |
| Payout Ratio | n/a |
| 1-Year Return | -52.53% |
| Volume | 25,782 |
| Open | 0.964 |
| Previous Close | 0.969 |
| Day's Range | 0.940 - 0.971 |
| 52-Week Low | 0.940 |
| 52-Week High | 2.249 |
| Beta | 0.77 |
| Holdings | 27 |
| Inception Date | Sep 15, 2021 |
About PSIL
Fund Home PageThe AdvisorShares Psychedelics ETF (PSIL) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed to provide exposure to the emerging global psychedelics industry. PSIL was launched on Sep 15, 2021 and is issued by AdvisorShares.
Asset Class Equity
Category Miscellaneous Sector
Stock Exchange NYSEARCA
Ticker Symbol PSIL
ETF Provider AdvisorShares
Top 10 Holdings
69.90% of assets| Name | Symbol | Weight |
|---|---|---|
| Mind Medicine (MindMed) Inc. | MNMD | 15.90% |
| BlackRock Liquidity Treasury Instl | TTTXX | 10.09% |
| Cybin Inc Ordinary Shares | CYBN.NE | 8.71% |
| COMPASS Pathways plc | CMPS | 6.44% |
| NRx Pharmaceuticals, Inc. | NRXP | 5.00% |
| Alkermes plc | ALKS | 4.89% |
| GH Research PLC | GHRS | 4.79% |
| Relmada Therapeutics, Inc. | RLMD | 4.75% |
| Atai Life Sciences N.V. | ATAI | 4.68% |
| Intra-Cellular Therapies, Inc. | ITCI | 4.65% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 25, 2023 | $0.00336 | Sep 29, 2023 |
| Sep 26, 2022 | $0.05421 | Sep 30, 2022 |
News
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics - AdvisorShares Psychedelics ETF (ARCA:PSIL)
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.
1 year ago - Benzinga